News >

Abemaciclib Improves PFS in Phase III MONARCH 3 Breast Cancer Trial

Jason M. Broderick @jasoncology
Published: Monday, Apr 24, 2017

Levi Garraway, MD, PhD

Levi Garraway, MD, PhD

Adding abemaciclib to letrozole or anastrozole improved progression-free survival (PFS) compared with either aromatase inhibitor alone in women with HR+/HER2-negative breast cancer enrolled in the phase III MONARCH 3 study, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication